Contact

The Future Gold
Standard in

Nerve Repair

Newrotex develops innovative silk-based medical
solutions for the nervous system.

The answer to “Can you repair nerves?” shouldn’t come with caveats. This is why Newrotex is set to disrupt existing approaches to surgical nerve repair. We’re on track to provide an alternative to autografts, the current gold standard in treatment for nerve injuries. A gold standard that requires sacrificing a healthy nerve from another part of the body. With our patented silk-based technology, we’ll deliver an off-the-shelf solution for surgical repair of the nerve. Without the need for long, complicated operations or using expensive donor tissues, Newrotex makes immediate treatment possible for patients who have suffered nerve injuries due to trauma, medical conditions, or surgical treatments.

Addressing an Unmet Need
in Nerve Repair

1.5

million

Annual operations for nerve injuries

Newrotex silk-based nerve products address the shortcomings of the solutions currently available.

Most of the world’s 1.5 million annual operations for nerve injuries are treated with autografts requiring a second injury and long surgery times, along with risking donor site morbidity and infection.

All of the major current solutions – autografts, allografts, and hollow tube conduits – are limited when repairing large gaps in nerves. Read Current Approaches for more about these and other shortcomings with current solutions for peripheral nerve repair.

Newrotex silk nerve products not only shorten procedure times, they are low-cost, simple to use, and effective for long-length nerve repairs.
Learn More

Why Silk is a Good Choice
for Nerve Repair

Over the past few decades, the potential biomedical applications of silk have been gaining interest at an exponential rate.

The versatility created by silk’s chemical structure allows for the production of fibres, gels, scaffolds, films, membranes, and powders. Silk has shown to have excellent cell affinity, and being biocompatible, with the ability to tailor biodegradation, silk is an ideal candidate for biomedical applications.

In terms of nerve repair, luminal silk fibres inside a vein or conduit guide regenerating axons, while the bioabsorbable, permeable tube allows nutrients to support nerve regeneration. Furthermore, silk products can be stored at room temperature, thereby removing the need for expensive cold storage and transportation.

Our Solution

SilkAxons®

Our first product is a 10cm implant made from bundles of luminal spider silk fibres that can be implanted into a vein or inserted into hollow conduits to support nerve re-growth. Pre-clinical studies have show that SilkAxons® support superior axonal regeneration.

Our second product is an off-the-shelf silk-based peripheral nerve conduit pre-filled with enhancing luminal silk fibres, negating the need to use a vein.

The fibres have proven nerve-regenerating properties and clinical trials show them to be comparable or superior to autografts. And with a porous tubular biocompatible sheath designed to encourage vascularisation, we provide a new and better approach to treating patients with peripheral nerve injuries.

Read more

Long-term Vision

Newrotex launched a first-in-human clinical trial in Q3 2025 using SilkAxons® to bridge large nerve gaps of up to 10cm (significantly more than current FDA approved devices). This study has generated foundational data for Newrotex’s global clinical strategy. Our goal is to commence a large study in 2026 culminating in an application for market approval in the USA and UK. We are also developing collaborations in which our silk platform technology may lead to further improvements in patient care, such as Schwann cell delivery and spinal cord injury repair.

Read more

Deprecated: Implicit conversion from float 0.15 to int loses precision in /home/newrotexuser/public_html/wp-content/themes/newrotex/page-home.php on line 368

Deprecated: Implicit conversion from float 0.15 to int loses precision in /home/newrotexuser/public_html/wp-content/themes/newrotex/page-home.php on line 368

Deprecated: Implicit conversion from float 0.15 to int loses precision in /home/newrotexuser/public_html/wp-content/themes/newrotex/page-home.php on line 368

Deprecated: Implicit conversion from float 0.15 to int loses precision in /home/newrotexuser/public_html/wp-content/themes/newrotex/page-home.php on line 368

Blog

Read All
July 24, 2026

Newrotex Spiders at the Houses of Parliament

We were honoured to be invited to the Houses of Parliament for the Life Sciences & Innovation Showcase yesterday. It was a powerful reminder of what’s possible when relentless innovators unite to tackle great challenges. We left inspired, energised and proud of our part in this ecosystem. Thank you to Venturefest Oxford and the Oxford Trust for supporting the Oxfordshire ecosystem. 

Read More
July 24, 2026

Winners of the MedTech Innovator Impact Award

  WE WON!!! Newrotex are absolutely delighted to have been awarded the MedTech Innovator Impact Award at MedTech Strategist Innovation Summit this week.  We talk all the time about the impact of living with nerve injuries. The average patient suffering from peripheral nerve injury is just 32 years old. For patients with large-gap peripheral nerve injuries, today’s options often fall short — leaving many facing lifelong disability, loss of function, and a limited quality of life.  Our goal with SilkAxons is to change that.

Read More
July 24, 2026

First In Human Trial Update

We’re pleased to share an early update from our first-in-human clinical trial of SilkAxons. The first cohort of patients has now reached the 6-month primary outcome milestone. To date, we have observed no adverse events, and all treated patients have already demonstrated meaningful functional recovery! Importantly, these cases all involved very large peripheral nerve gaps (8–10 cm) — injuries that remain highly challenging to treat with existing standards of care. Seeing effective recovery across this initial group is an encouraging early signal. While these results are preliminary and the study remains ongoing, crossing this milestone safely and successfully represents an important step forward for our program. We remain focused on disciplined clinical execution, rigorous follow-up, and transparent reporting as additional patients reach key endpoints We want to thank the patients, the team at the Panama Clinic and our CRO partners who have made this progress possible.  We look forward to sharing further updates as the trial advances.  

Read More
July 24, 2026

BBC News Visit Newrotex

  We had the pleasure of welcoming the BBC News team to our lab at the Wood Centre for Innovation last week to hear all about our pioneering research. Thank you to Jamie Morris for his fantastic article which you can read here  https://www.bbc.co.uk/news/articles/ckgngvr2ye1o

Read More